Eric Padron, MD

Where You Are:

Eric Padron, MD

Medical Oncology

For Consultation Requests or Referrals: (888) 860-2778

 
 

BOARD CERTIFICATION:
          •  Internal Medicine - Medical Oncology

FELLOWSHIP:
          •  Moffitt Cancer Center - Hematology/Oncology

RESIDENCY:
          •  University of Florida Shands Hospital

MEDICAL SCHOOL:
          •  University of Florida - MD

  • Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2014 Nov. Pubmedid: 25465125.

  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.

  • Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer. 2014 Nov. Pubmedid: 25410759.

  • Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-812. Pubmedid: 24764152.

  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun;123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.

  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.

  • Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar;12(3):172-178. Pubmedid: 24927265.

  • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014;9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.

  • Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec;26(4):365-375. Pubmedid: 24507813.

  • Patnaik MM, Padron E, Laborde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-Kali A, Pardanani A, Ali NA, Komrokji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Oct;27(10):2112. Pubmedid: 24104213.

  • Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct;6(5):485-487. Pubmedid: 24083503.

  • Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S295-S299. Pubmedid: 24290214.

  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Aug;121(25):5068-5077. Pubmedid: 23632888.

  • Padron E, Abdel-Wahab O. Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol. 2013 Aug;31(19):2374-2376. Pubmedid: 23690427.

  • Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul;27(7):1504-1510. Pubmedid: 23531518.

  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr. Pubmedid: 23605934.

  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.

  • Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct;19(4 Suppl):4-15. Pubmedid: 23042420.

  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.

  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.

  • Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb;3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.

  • Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec;12(4):354-368. Pubmedid: 21964863.

  • Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb;4(1):61-69. Pubmedid: 21322779.

  • Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011;(62):71.

Generally, my clinical interests are the care and treatment of patients with adult myeloid malignancies including MDS, AML and Myeloproliferative Neoplasms (MPNs) with a specific interest in the Myeloproliferative/Myelodysplastic (MDS/MPN) syndromes of which CMML is a member.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions